Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth ... year to $13.5 billion from $9.3 billion. Earnings per share came in at $4.99, underperforming Wall ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing ... Doses may continue to increase to a maximum of 15 mg per week, based on individual needs.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss ... of $5.01 per share.

On TikTok, where the 31-year-old mother of three chronicled her weight loss journey ... ovarian syndrome (PCOS), her doctor prescribed Zepbound to help with symptoms of the condition as well ...